SEC Form 4 · accession 0001209191-17-022684
Atara Biotherapeutics, Inc. · ATRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John McGrath
Officer — EVP & Chief Financial Officer
Period of report
Mar 22, 2017
Accepted (ET)
Mar 23, 2017 · 8:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001604464
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Mar 22, 2017 | S | 7,500 | $20.27 | D | 119,327 | D | |
| Common StockF3 | Mar 23, 2017 | S | 6,500 | $21.08 | D | 112,827 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016.
- F2The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.10 to $20.50. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.80 to $21.45. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.